Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation

Kidney International

Volumn 85, Issue 6, 2014, Pages 1267-1268

  Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; CHRONIC ALLOGRAFT NEPHROPATHY; DRUG CLEARANCE; DRUG EXPOSURE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOASSAY; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; WITHIN PATIENT VARIABILITY; BLOOD; DRUG EFFECTS; FEMALE; GRAFT REJECTION; MALE;

FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; TACROLIMUS;

EID: 84901848017     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.484     Document Type: Note

References (10)

1. Passey C, Birnbaum AK, Brundage RC et al. Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics 2012; 13: 1141-1147.
2. Borra LC, Roodnat JI, Kal JA et al. High withinpatient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 2757-2763.
3. Sapir-Pichhadze R, Wang Y, Famure O et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int 2014; 85: 1404-1411.
4. Egashira K, Sasaki H, Higuchi S et al. Fooddrug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats. Drug Metab Pharmacokinet 2012; 27: 242-247.
5. Bekersky I, Dressler D, Mekki QA. Effect of low-and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 2001; 41: 176-182.
6. Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther 2012; 92: 727-736.
7. Kahan BD, Welsh M, Urbauer DL et al. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J Am Soc Nephrol 2000; 11: 1122-1131.
8. Massey EK, Tielen M, Laging M et al. The role of goal cognitions, illness perceptions and treatment beliefs in self-reported adherence after kidney transplantation: a cohort study. J Psychosom Res 2013; 75: 229-234.
9. De Bleser L, Matteson M, Dobbels F et al. Interventions to improve medicationadherence after transplantation: a systematic review. Transpl Int 2009; 22: 780-797.
10. Wu MJ, Cheng CY, Chen CH et al. Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients. Transplantation 2011; 92: 648-652.